-Advertisement-
-Advertisement-
FDA Alerts
Mirum Pharmaceuticals submits new drug application for Chenodiol for CTX
Mirum Pharmaceuticals announced the submission of a New Drug Application to the U.S. Food and Drug Administration for chenodiol for the treatment of cerebrotendinous xanthomatosis (CTX), according to a press release. CTX is a rare genetic disorder affecting cholesterol metabolism, leading to severe symptoms and neurologic deterioration. The submission follows...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Contact
© 2024 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved